Early morning hyperglycemia is sometimes called the “dawn phenomenon.” Left untreated, it can drive poorer outcomes. How can ...

Novo Nordisk said that if approved for use, insulin icodec would reduce the number of basal insulin injections needed per year for type 2 diabetics from 365 to 52, a significant reduction in ...

Niyondiko, N. (2024) Clinical Management of Diabetic Ketoacidosis in Pregnancy: A Review of Current Literature. Open Access Library Journal, 11, 1-25. doi: 10.4236/oalib.1112246 .

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets ...

Maxim Group analyst Jason McCarthy has maintained their bullish stance on RZLT stock, giving a Buy rating yesterday. Jason McCarthy has given ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Indianapolis, IN, USA - June 17, 2014: Researchers at Lilly Research Laboratories, shown here on June 17, 2014, developed ...